Posted on 2/25/2005, 2:00:03 AM by neverdem
IRVINE, Calif. - Hans S. Keirstead might be the Pied Piper of stem cells - and not just because he makes rats walk. He also helped lure Californians to the polls last fall to approve spending $3 billion of the state's money on embryonic stem cell research over the next decade. But he has critics who worry that he may be leading their new field too far, too soon into uncharted territory.
Dr. Keirstead, an assistant professor at the University of California campus here, has been making paralyzed rats walk again, using a treatment based on human embryonic stem cells. Next year he and his corporate partner, Geron, plan to try treating people who have recent spinal cord injuries, in what would almost certainly be the first human trial of any therapy derived from such cells.
"You've got a patient community out there that is in desperate need," Dr. Keirstead said in an interview. "If the treatment is safe, let's get it out there and try it."
And to those who argue that it is too soon to test his technique on humans, he has an answer. "There will always be people who say slow down, slow down," he said. "I guarantee you none of them have relatives in wheelchairs."
With his gung-ho attitude, the good looks of a surfer and a compelling story to tell, Dr. Keirstead, 37, emerged as one of the leading scientific voices behind the movement that persuaded California voters last November to approve a measure to sidestep federal funding restrictions on stem cell research. His supporters included people with spinal cord injuries, most notably Christopher Reeve, the wheelchair-bound actor who taped a campaign ad citing Dr. Keirstead's research just before he died in October.
But for all of Dr. Keirstead's fans and backers, a number of researchers in California and elsewhere say the scientific validity of his work has not been proved and the technique might not be ready for testing in people. A failure in the first high-profile human test could dash some of the hope spawned by the passage of the California ballot measure.
"A lot of things make rats better," said Jerry Silver, a neuroscientist at Case Western Reserve University, who argued that Dr. Keirstead should test his treatment in dogs or monkeys first. "You can't announce you are going into humans because you've gotten good results in rats."
Mark H. Tuszynski, a professor and director of the center for neural repair at the University of California, San Diego, echoed that view. "I think the jury is still out," he said, "on whether this is a useful approach." Dr. Tuszynski, co-founder of a company trying to use gene therapy to treat neurological diseases, said he would prefer to see "more compelling evidence" from Dr. Keirstead's work before human testing.
The new California stem cell research board that was set up after passage of last fall's ballot measure, Proposition 71, is still organizing itself and figuring out how to begin awarding public grants to scientists. But Dr. Keirstead has been able to speed forward, fueled by money from Geron, a California biotechnology company, which is eager to demonstrate to investors that practical use of stem cells is not a distant dream.
Because embryonic stem cells can form any other kind of cell in the body, scientists envision using them to replace cells and tissues that have been damaged by disease or injury.
The Bush administration has restricted federally funded research to certain colonies of stem cells, pointing out that creating additional such cells involves the destruction of human embryos.
But proponents of the research argue that the early embryos have no feeling or consciousness and that most of them used in research are left over from fertility clinics and are destined to be discarded anyway.
California's ballot measure was propelled by people with diseases and their families and backed by big campaign contributions by some wealthy businessmen.
Robert N. Klein, a Palo Alto real estate developer who has a son with diabetes, helped draft the ballot initiative and put his money behind the vote effort. After passage he was named chairman of the board overseeing distribution of the $3 billion.
Mr. Klein said it was "extremely welcome" that, under Dr. Keirstead, embryonic stem cell therapy was moving toward clinical trials. He said the public needed to know in advance, however, that as with many new therapies, the first trial is not expected to succeed. "It may take several years, or many years, to refine," he said.
Dr. Keirstead's work was a rallying point during the Proposition 71 campaign; he gave 14 speeches to various civic, political and business groups to whom he showed a video of his rat research.
In it, an untreated rat struggled to pull itself along the ground using its forelimbs as its paralyzed hind legs, tail and belly scraped along the ground. A rat treated with Dr. Keirstead's cells was then shown moving its hind legs, though not perfectly, and keeping its tail in the air.
"Stem cells have already cured paralysis in animals," Mr. Reeve, the actor, said in the commercial he filmed, which was broadcast after his death. He urged voters to "stand up for those who can't."
But some spinal cord researchers criticized Dr. Keirstead for having shown his video for three years but not publishing his work with rats in a peer-reviewed journal that would allow experts to truly evaluate it.
Dr. Keirstead said he was in the process of publishing his results with rats, but that he had wanted to do other tests before publishing. He expects to release further results well before starting clinical trials next year. He said, though, that showing the video before publication, even at the risk of annoying fellow scientists, was important to give patients hope.
"I've had people call me up and say, 'I'm about to commit suicide, do you have anything to stop me?' " he said. "People don't realize how close we are."
Indeed, during a two-hour interview in Dr. Keirstead's cramped office here, his phone rang several times with calls from injured people, some volunteering to be guinea pigs in any study he conducts.
John W. McDonald, director of the international spinal cord injury and paralysis center at the Kennedy Krieger Institute in Baltimore, said "to date, not enough has been shown" by Dr. Keirstead and Geron to allow federal regulators to authorize a clinical trial. Even so, he said Dr. Keirstead was being unfairly criticized.
"Scientists aren't too kind to other scientists' receiving too much attention," said Dr. McDonald, who himself received notice for therapy that restored some minor movement and sensation in Mr. Reeve. "I think that's what you're seeing."
Dr. Keirstead's optimism has won him praise from people with spinal cord injuries and their families.
"He cares about patients intensely; it's not just a job for him," said Don C. Reed, a retired schoolteacher and Proposition 71 advocate from Fremont, Calif., whose son, Roman, was paralyzed in a college football accident 10 years ago.
"I held in my hand a rat that had walked again after being paralyzed," Mr. Reed said, "and this with my son sitting there in his wheelchair."
For all their promise, stem cells could pose dangers if not carefully controlled. Scientists do not envision implanting raw stem cells into patients because the cells might turn into undesirable types of tissues. The idea, instead, is to turn embryonic stem cells into the desired type of cell, such as heart cells or liver cells, in the laboratory and then transplant these more specialized cells.
Dr. Keirstead and other scientists in his laboratory figured out how to turn embryonic stem cells into a nearly pure population of brain cells called oligodendrocytes, which form the insulation around neurons. Without this insulation, the neurons cannot easily carry the signals that tell muscles to move or relay sensations to the brain.
They described the work in a paper published by the journal Glia in November. "This is the first report of getting oligodendrocytes in the numbers they did and the purity they did," said Dr. Mahendra Rao, a stem cell researcher at the National Institute on Aging who has also tried to make oligodendrocytes.
But it remains unclear how much of a difference this will make to people with spinal cord injuries. People lose movement and sensation mainly because the nerves themselves - the wires - are cut or damaged. Simply restoring the insulation will not help repair a broken wire.
But Dr. Keirstead said that some neurons remain intact after an injury but lose their insulation, called myelin. So, in theory, restoring the myelin to those neurons could help restore at least some movement or sensation. Such a treatment, he said, would have to be given within days of the injury; otherwise, the formation of scar tissue would probably render the treatment ineffective.
Dr. Keirstead, who was raised in Canada, received his doctorate from the University of British Columbia and won an award for the country's best zoology-related thesis in 1995. He helped start a company in Vancouver, Neuro Therapeutics, to develop spinal cord injury treatments based on that work, which did not involve stem cells. But the company ran out of money. Dr. Keirstead came to Irvine in 2000 to join the Reeve-Irvine Research Center on spinal cord injuries. It was set up by Mr. Reeve and Joan Irvine Smith, a philanthropist and member of the family for whom Irvine is named.
He started his second company, Ability Biomedical, with another University of California, Irvine, faculty member to treat multiple sclerosis. More successful than his first venture, it was sold last summer to Medarex, a publicly traded biotechnology company, for $4.7 million up front and possibly $3.6 million later.
To work with embryonic stem cells, Dr. Keirstead turned to Geron, the Menlo Park, Calif., company that had financed the research leading to the original isolation of human embryonic stem cells at the University of Wisconsin in 1998 and that controls some of the fundamental patent rights in the field.
Thomas B. Okarma, Geron's president, said next year's trial of Dr. Keirstead's approach would mainly check for safety. The oligodendrocytes would be inserted into the spinal columns of patients at the same time they have an operation that is common after spinal cord injury and is aimed at preventing further damage.
Dr. Okarma denied that the trial was premature or risky, but noted that Geron would have to apply to the Food and Drug Administration next year and receive approval before beginning the trial. Asked about the criticism from others, he responded: "There's a lot of jealousy. What can I tell you? This is the hottest thing in medicine."
Geron is providing about $500,000 a year to Dr. Keirstead's lab. As long as that continues, Dr. Keirstead said that he did not need any grants from the Proposition 71 ballot measure he helped pass and that he might not even have the capacity to use the money. "There's only so much I can do," he said.
But then he stopped and thought again, before saying that state money would be welcome. "Research goes as fast as the dollars," he said.
ping
FReepmail me if you want on or off my health and science ping list.
>>To work with embryonic stem cells, Dr. Keirstead turned to Geron, the Menlo Park, Calif., company that had financed the research leading to the original isolation of human embryonic stem cells at the University of Wisconsin in 1998 and that controls some of the fundamental patent rights in the field.
What a scam this is. We just turned over $3 billion in taxpayer money to these yoyos. Geron has never had revenue in excess of $6 million annually, yet they have been able to rack up $188 million in operating losses. I guess they'll be pretty good at helping spend that $3 billion.
|
Sat Nov 27,11:14 PM ET |
SEOUL (AFP) - A South Korean woman paralyzed for 20 years is walking again after scientists say they repaired her damaged spine using stem cells derived from umbilical cord blood.
|
Hwang Mi-Soon, 37, had been bedridden since damaging her back in an accident two decades ago.
Last week her eyes glistened with tears as she walked again with the help of a walking frame at a press conference where South Korea (news - web sites) researchers went public for the first time with the results of their stem-cell therapy.
They said it was the world's first published case in which a patient with spinal cord injuries had been successfully treated with stem cells from umbilical cord blood.
Though they cautioned that more research was needed and verification from international experts was required, the South Korean researchers said Hwang's case could signal a leap forward in the treatment of spinal cord injuries.
The use of stem cells from cord blood could also point to a way to side-step the ethical dispute over the controversial use of embryos in embryonic stem-cell research.
"We have glimpsed at a silver lining over the horizon," said Song Chang-Hoon, a member of the research team and a professor at Chosun University's medical school in the southwestern city of Kwangju.
"We were all surprised at the fast improvements in the patient."
Under TV lights and flashing cameras, Hwang stood up from her wheelchair and shuffled forward and back a few paces with the help of the frame at the press conference here on Thursday.
"This is already a miracle for me," she said. "I never dreamed of getting to my feet again."
Medical research has shown stem cells can develop into replacement cells for damaged organs or body parts. Unlocking that potential could see cures for diseases that are at present incurable, or even see the body generate new organs to replace damaged or failing ones.
So-called "multipotent" stem cells -- those found in cord blood -- are capable of forming a limited number of specialized cell types, unlike the more versatile "undifferentiated" cells that are derived from embryos.
However, these stem cells isolated from umbilical cord blood have emerged as an ethical and safe alternative to embryonic stem cells.
Clinical trials with embryonic stem cells are believed to be years away because of the risks and ethical problems involved in the production of embryos -- regarded as living humans by some people -- for scientific use.
In contrast, there is no ethical dimension when stem cells from umbilical cord blood are obtained, according to researchers.
Additionally, umbilical cord blood stem cells trigger little immune response in the recipient as embryonic stem cells have a tendency to form tumors when injected into animals or human beings.
For the therapy, multipotent stem cells were isolated from umbilical cord blood, which had been frozen immediately after the birth of a baby and cultured for a period of time.
Then these cells were directly injected to the damaged part of the spinal cord.
"Technical difficulties exist in isolating stem cells from frozen umbilical cord blood, finding cells with genes matching those of the recipient and selecting the right place of the body to deliver the cells," said Han Hoon, president of Histostem, a government-backed umbilical cord blood bank in Seoul.
Han teamed up with Song and other experts for the experiment.
They say that more experiments are required to verify the outcome of the landmark therapy.
"It is just one case and we need more experiments, more data," said Oh Il-Hoon, another researcher.
"I believe experts in other countries have been conducting similar experiments and accumulating data before making the results public."
January 7, 2005
There were no headlines or editorials, for example, when Song Chang-Hoon, a professor at South Korea's Chosun University's medical school, told the story of Hwang Mi-Soon, a 37-year-old paraplegic who, after being paralyzed for 20 years, was able to rise from her wheelchair and is now shuffling back and forth with the aid of a walker after umbilical cord blood stem cells were injected into her spine.
Some of the studies that led to this virtually unreported Korean miracle were ironically funded by the Christopher Reeve Paralysis Foundation, and had Reeve sought the same therapy instead of obsessing about embryonic stem cells, he might have gotten out of his wheelchair as well.
The unreported problems with embryonic stem cells is that they suffer immune system rejection problems, they often cause tumors such as teratomas, and they are extremely difficult to convert to any specific type of cell.
Adult stem cells have been used therapeutically since the 1980s, and there are almost 80 therapies using them -- actual treatments, not theory or research. There have been more than 250 adult stem cell clinical trials. There are zero treatments using embryonic stem cells, and there have been zero clinical trials.
The simple truth is that most progress in stem cell research is being made using the adult rather than the embryonic variety. And the truth is that a biased media is largely ignoring that fact, while portraying opponents of embryonic stem cell research as heartless Bible-thumpers prolonging human suffering.
Daniel John Sobieski, Garfield Ridge
In 2000, Israeli scientists implanted Melissa Holley's white blood cells into her spinal cord to treat the paraplegia caused when her spinal cord was severed in an auto accident. Melissa, who is 18, has since regained control over her bladder and recovered significant motor function in her limbs - she can now move her legs and toes, although she cannot yet walk.
Success Stories with Adult Stem Cells Coming in Almost Too Fast to Track
January 20, 2005 LifeSiteNews.com - Success stories about adult stem cell treatments are coming in so fast that LifeSiteNews.com, one of the few newswire services to follow the issue closely, is having trouble keeping up. While most disease research organizations, such as Juvenile Diabetes, Multiple Sclerosis and the Canadian Cancer Society, continue to promote the use of living embryonic human beings for experimentation, the only success stories to date have all come from the use of adult stem cells.
Adult stem cells are distinguished from those derived from embryos, and do not necessarily mean only those from adult patients. Adult stem cells are being found in abundance in blood taken from the umbilical cord for example. Three stories have appeared only today that show where the real hope lies in stem cell research.
A young American woman, Erica Nader, injured in a car accident and paralysed from the upper arms down, has been treated for a spinal cord injury using stem cells taken from her nose and implanted in the spinal cord at the site of the injury. The procedure, which is performed nowhere else in the world was performed by a team of surgeons in Portugal at Lisbon's Egas Moniz Hospital. “After three years, magnetic imaging resonance tests (MRI's) show that the cells indeed promote the development of new blood cells and synapses, or connections between nerve cells,” says Dr. Carlos Lima, chief of the Lisbon team.
Nader is recovering slowly but steadily. She was paralyzed from her biceps down and three years ago had no finger movements. Now, she can do exercises on a floor mat and walk with leg braces on a treadmill.
Treating children suffering from blood disorders such as leukemia with adult stem cells is common, but treatment for adults is difficult because of the scarcity of cells that can be taken from an adult. Today the American Society of Hematology reports that the problem is being overcome by a new technique that combines two cord blood units from different donors for transplantation into adult or adolescent leukemia patients. Cord blood is more tolerant of differences between patient and donor, making it possible to perform cord blood transplants without an exact match.
“With this new technique of increasing the dose by combining two units, this procedure could be made available to thousands more patients and has the potential to save many lives,” said one of the authors of the University of Minnesota study.
Researchers at the Massachusetts General Hospital have found that the spleen may be a source of potential adult stem cells that contain a protein called Hox11, which is associated with embryonic development and limb regeneration. Previously it was believed that the protein was only found in embryos. The spleen was also found to contain stem cells that were involved in the production of insulin. The new discovery, says Dr. Denise Faustman, director of the hospital's Immunobiology Laboratory, could mean that “There may be a previously undiscovered pocket of primitive stem cells in the spleen that are important for healing several types of damage or injury.”
Paraplegic improving after stem-cell implant
http://www.indystar.com/articles/5/209449-5235-047.html
Cord Blood Transplantation Now a Viable Option for Adult Leukemia Patients
http://releases.usnewswire.com/GetRelease.asp?id=41886
I oppose the use of embryonic stem cells and am in favor of using the stem cells from other sources.
Guilt by association, that's good enough for the dems with consultants who worked for the Swiftees, while they yap about McCarthyism. Oh the humanity!
These dems are so clueless, they can't imagine that about 2 out of 3 veterans voted against Kerry. I believe folks on active duty had numbers of about 7 out of 10 voting against Kerry.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.
